Cogent Biosciences (COGT) net assets (shareholders' equity)

Net assets · fiscal 2025
$636.37M

Cogent Biosciences (COGT) had net assets of $636.37M at the end of fiscal 2025 (December 31, 2025). That is 148.3% higher than the $256.29M of fiscal 2024. Figures as of 19 Nov 2026, 00:15 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Net assets, fiscal 2025
$636.37M
Change on fiscal 2024
+148.3%
Growth, 5 years
+22.1% a year
Highest on record
$636.37Mfiscal 2025
Lowest on record
-$48.85Mfiscal 2017
Fiscal years on record
92017–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Cogent Biosciences net assets (shareholders' equity), in more detail

Over the five fiscal years to 2025 net assets grew at a compound 22.1% a year. Across the 9 fiscal years on record (2017–2025), the highest was $636.37M in fiscal 2025 and the lowest -$48.85M in fiscal 2017.

History · 9 fiscal years

Net assets by fiscal year

Cogent Biosciences net assets (shareholders' equity), year by year

Cogent Biosciences (COGT) net assets (shareholders' equity) by fiscal year
Fiscal yearNet assetsChangeYear ended
2025$636.37M 148.3% up
2024$256.29M 0.6% down
2023$257.80M 0.8% up
2022$255.74M 19.4% up
2021$214.18M 8.7% down
2020$234.67M 638.8% up
2019$31.76M 47.3% down
2018$60.23M—
2017-$48.85M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value.

How to read it

Large buybacks and write-offs shrink it without the business getting worse, so a falling or negative figure needs the reason before a verdict.

Net assets at health care companies of similar size

Net assets of Cogent Biosciences and comparable companies
CompanyNet assetsFiscal year
Teleflex TFX$3.12B2025
Mirum Pharmaceuticals MIRM$314.69M2025
Veradermics MANE$143.46M2025
Grifols GRFS€5.27B2025
Cogent Biosciences COGT$636.37M2025
GRAIL GRAL$2.58B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on COGT

Cogent Biosciences, figure by figure

Cogent Biosciences (COGT) overview: price, valuation and scorecardAll health care companies by market value

Cogent Biosciences net assets (shareholders' equity): questions and answers

What are Cogent Biosciences's net assets?

Cogent Biosciences (COGT) had net assets of $636.37M at the end of fiscal 2025 (December 31, 2025). That is 148.3% higher than the $256.29M of fiscal 2024.

What is the growth rate of Cogent Biosciences's net assets?

Over the five fiscal years to 2025 net assets grew at a compound 22.1% a year.

What are the highest and lowest net assets figures on record for Cogent Biosciences?

Across the 9 fiscal years on record (2017–2025), the highest was $636.37M in fiscal 2025 and the lowest -$48.85M in fiscal 2017.

How is Cogent Biosciences's net assets calculated?

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value. For Cogent Biosciences it is on record here for 9 fiscal years, 2017 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Cogent Biosciences (COGT) net assets (shareholders' equity)”, data as of 19 November 2026. https://funkfolio.com/stock/COGT/net-assets

Underlying data: the company's filings with the SEC and Yahoo Finance.